EGFR x c-MET

Assets acting on this target.

Class
Dual EGFR and MET targeting
Pathway
simultaneously blocks EGFR and c-MET receptor tyrosine kinase signaling, addressing MET-amplification-driven resistance to EGFR-targeted therapy in NSCLC

EGFR and c-MET are both receptor tyrosine kinases (RTKs) that sit on the cell surface and, when activated by their ligands, initiate intracellular signaling cascades that promote cell growth, survival, and migration. In many epithelial cancers, particularly non-small cell lung cancer (NSCLC), mutations in EGFR make this receptor constitutively active, driving uncontrolled proliferation. Anti-EGFR therapies can effectively suppress this, but tumors frequently develop resistance by amplifying c-MET, which reactivates the same downstream growth pathways through a parallel receptor. A bispecific antibody engineered to bind both EGFR and c-MET simultaneously blocks ligand-driven activation of each receptor and can trigger their removal from the cell surface, addressing tumor growth through two convergent nodes at once. This dual-targeting strategy is designed to treat EGFR-mutant tumors upfront while also suppressing the c-MET-mediated escape route that limits the durability of EGFR-only therapies, and to address tumors that already show combined EGFR/c-MET dysregulation. Beyond NSCLC, this mechanism has relevance in other EGFR-driven or c-MET-amplified carcinomas. Because the molecule is a full antibody rather than a small molecule, it also carries an antibody's characteristic properties, including engagement of immune effector functions to help eliminate targeted cells.

By indication

Related mechanisms

EGFR x c-MET drugs compared

9 drugs, stage by indication
9 drugs acting on EGFR x c-MET: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AmivantamabGenmab, Johnson & Johnsonbispecific antibodyApprovedApproved in Non-Small Cell Lung Cancer; Phase 3 in Colorectal Cancer; Phase 3 in Head and Neck Squamous Cell Carcinoma
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)Rybrevant FasproJohnson & Johnsonbispecific antibodyApprovedApproved in Head and Neck Squamous Cell Carcinoma; Approved in Non-Small Cell Lung Cancer
ALK202Shanghai Allink Biotherapeutics Co., Ltd.bispecific antibody-drug conjugatePhase 2Phase 2 in Non-Small Cell Lung Cancer
BafisontamabShanghai EpimAb Biotherapeuticsbispecific antibodyPhase 2Phase 2 in Advanced Metastatic Colorectal Cancer; Phase 1/2 in Non-Small Cell Lung Cancer
PamvatamigBetta Pharmaceuticals Co., Genmab, Merus N.V.bispecific antibodyPhase 2Phase 2 in Non-Small Cell Lung Cancer
SKB571Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.antibody-drug conjugatePhase 2Phase 2 in Non-Small Cell Lung Cancer
225Ac-FPI-2068AstraZenecaradiopharmaceuticalPhase 1Phase 1 in Non-Small Cell Lung Cancer
QLS5316Qilu Pharmaceuticalsmall moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer
Tilatamig samrotecanAstraZenecaantibody-drug conjugatePhase 1Not recorded

← all mechanisms